Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531894 · ClinicalTrials.gov registry record · Phase 2
Continuation Study of the Oral AKT Inhibitor GSK2110183
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01531894 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT01531894, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This multicenter, non-randomized, open-label, treatment continuation or 'rollover' study was designed to provide continued access to eligible subjects who had previously participated in a GSK2110183 study (parent study) sponsored by GlaxoSmithKline (GSK) or another research organization working on behalf of GSK. Eligible subjects had previously received clinical benefit from continued treatment and had to have ad an acceptable safety profile with GSK2110183. Subjects who had participated in a GSK2110183 combination study with an approved anti-cancer agent were also be eligible to enroll in this rollover study. Subjects who participated in combination studies with two investigational compounds (one being GSK2110183) were not eligible for this rollover study. Subjects were enrolled by cohort based on the duration and treatment received while in their parent study. Safety assessments (physical examinations, vital sign measurements, 12-lead electrocardiograms, echocardiograms or multiple-gated acquisition scans, clinical laboratory assessments and monitoring of adverse events) were evaluated during this study. Disease assessment were performed using local standard of care imaging practices and criteria appropriate for disease type and location.
Interventions
- DRUG GSK2110183 (afuresertib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-02-08 |
| Est. Completion | 2018-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531894
The ClinicalTrials.gov registry entry for NCT01531894 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2110183 (afuresertib) is the first listed.
NCT01531894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531894 about?
NCT01531894 is a clinical study titled "Continuation Study of the Oral AKT Inhibitor GSK2110183". This multicenter, non-randomized, open-label, treatment continuation or 'rollover' study was designed to provide continued access to eligible subjects who had previously participated in a GSK2110183 study (parent study) sponsored by GlaxoSmithKline (GSK) or another research organization working on b...
What is the current status of trial NCT01531894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2012-02-08. Estimated completion is 2018-06-20.
What interventions are being tested in trial NCT01531894?
The interventions under investigation include: GSK2110183 (afuresertib) (DRUG).
Who is sponsoring clinical trial NCT01531894?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.